From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments

Keyphrases

• Psoriasis Treatment 100%
• Psoriasis 100%
• Masterclass 100%
• Orally Administered 75%
• Quality of Life 50%
• Medicare 50%
• Psoriatic Arthritis 50%
• Tumour Necrosis Factor Inhibitor (TNFi) 50%
• Anti-interleukin-23 50%
• Patient Management 25%
• Immune Response 25%
• Comorbidity 25%
• Treatment Options 25%
• Interleukin-23 (IL-23) 25%
• Mode of Delivery 25%
• Interleukin-17 (IL-17) 25%
• Psoriasis Disease 25%
• Emerging Treatments 25%
• Rapidly Evolving 25%
• Chronic Inflammatory Skin Disease 25%
• Disease Control 25%
• Personalized Care 25%
• Arthritis 25%
• Treatment Landscape 25%
• Receptor Antagonist 25%
• Highly Selective 25%
• Financial Barriers 25%
• Multiple Diseases 25%
• Barriers to Access 25%
• IL-36 25%
• Generalized Pustular Psoriasis 25%
• IL-23R 25%
• Puerto Rico 25%
• Novel Formulations 25%
• Shaping the Future 25%
• Therapeutic Landscapes 25%
• Traditional Mode 25%
• Spesolimab 25%
• Targeted Biologic Therapies 25%
• Anti-interleukin-17 25%
• Deucravacitinib 25%
• Tyrosine Kinase 2 Inhibitor 25%
• Interchangeable Biosimilar 25%

Medicine and Dentistry

• Psoriasis 100%
• Dermatology 100%
• Biological Product 83%
• Quality of Life 33%
• Medicare 33%
• Psoriatic Arthritis 33%
• Interleukin 23 33%
• Interleukin 17 33%
• TNF Inhibitor 33%
• Comorbidity 33%
• Clinician 16%
• Patient Care 16%
• Interleukin 12 16%
• Cytokine 16%
• Protein Tyrosine Kinase 16%
• Receptor Antagonist 16%
• Dermatitis 16%
• Emerging Treatment 16%
• Arthritis 16%
• Biological Therapy 16%
• Receptor Antibody 16%
• Biosimilar 16%
• Interleukin 23 Receptor 16%
• Generalized Pustular Psoriasis 16%
• Diseases 16%
• Treatment Option 16%
• Preference 16%